Modality
ERT
MOA
STINGag
Target
GPRC5D
Pathway
Amyloid
PSP
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
~Jan 2020
→ ~Apr 2021
Phase 3
~Jul 2021
→ ~Oct 2022
NDA/BLA
Jan 2023
→ Oct 2027
NDA/BLACurrent
NCT08282023
1,152 pts·PSP
2023-01→2027-10·Completed
1,152 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-061.5y awayPh3 Readout· PSP
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2027-10-06 · 1.5y away
PSP
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08282023 | NDA/BLA | PSP | Completed | 1152 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |